© 2003 European Society of Cardiology
Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate
Department of Medicine and Therapeutics, Clinical Sciences Building, University of Leicester, Leicester Royal Infirmary Leicester LE2 7LX, UK
* Corresponding author. Tel.: 44-116-252-3125; fax: 44-116-252-3108. E-mail address: is11{at}le.ac.uk
 |
Abstract |
|---|
Background: Plasma natriuretic peptide levels may be useful in the diagnosis of heart failure. The available natriuretic peptide assays differ markedly in their performance characteristics. In addition, plasma levels are influenced by a number of factors including age and gender.
Aims: The aim of this study was to describe, in a healthy population, the influence of clinical and echocardiographic parameters on three natriuretic peptide moieties.
Methods: 1360 individuals were screened for the presence of left ventricular systolic dysfunction. We identified a cohort (n=720) of men aged 45–80 years (n=417) and women aged 55–80 years (n=303). None had history of cardiovascular disease or were taking any cardiovascular medication. All had normal echocardiographic and ECG findings. B-type (BNP), N-terminal pro-B-type (N-BNP) and N-terminal pro-Atrial (N-ANP) natriuretic peptides were assayed using in-house immunoluminometric assays.
Results: Of the considered clinical variables, only gender and heart rate (each P<0.005) were independently associated with levels of all three natriuretic peptides. Plasma levels of N-ANP (15%), BNP (25%) and N-BNP (75%) were higher in women compared to men. An increase in heart rate of 10 bpm corresponded to a reduction of 9% in N-ANP or BNP and a 15% reduction in N-BNP. Each 10 years of age was associated with 16% and 74% increase in ANP and N-BNP levels, respectively, but no increase in plasma BNP. Left ventricular ejection fraction could be assessed in 582 (81%) subjects and correlated positively with N-ANP (rs=6.48x10–3, P<0.001) and BNP (rs=2.4x10–2, P<0.001) but not N-BNP (P=0.405). No parameter of diastolic function was associated with any peptide level.
Conclusions: In this healthy population, plasma levels of N-ANP, BNP and N-BNP were variably influenced by clinical covariates. While all three peptides were higher in women, only N-ANP and N-BNP were influenced by age. Levels of all peptides were inversely correlated with heart rate. Using this immunoluminometric assay, plasma BNP is not influenced by age, in contrast to N-ANP and N-BNP. In constructing normal ranges for diagnostic use, covariates such as age and gender must be considered, in addition to the format of assay being used.
Key Words: Natriuretic peptides • Reference range
Received March 12, 2003; Accepted June 16, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Voors, S. von Haehling, S. D. Anker, H. L. Hillege, J. Struck, O. Hartmann, A. Bergmann, I. Squire, D. J. van Veldhuisen, K. Dickstein, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study Eur. Heart J., May 2, 2009; 30(10): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department QJM, November 1, 2008; 101(11): 831 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H Willis Spectrum bias--why clinicians need to be cautious when applying diagnostic test studies Fam. Pract., October 1, 2008; 25(5): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weber, M. Burian, I. Dragutinovic, H. Moellmann, H. Nef, A. Elsaesser, V. Mitrovic, C. Hamm, and G. Geisslinger Genetic polymorphism of the type A human natriuretic peptide receptor (NPR-A) gene contributes to the interindividual variability in the BNP system Eur J Heart Fail, May 1, 2008; 10(5): 482 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF]
|
|
|
|
 |
|
 K Chatha, M Alsoud, M J Griffiths, A Elfatih, K Abozguia, R C Horton, S J Dunmore, and R Gama B-type natriuretic peptide in reversible myocardial ischaemia. J. Clin. Pathol., November 1, 2006; 59(11): 1216 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Sharma, D C Gaze, D Pellerin, R L Mehta, H Gregson, C P Streather, P O Collinson, and S J D Brecker Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease. Heart, October 1, 2006; 92(10): 1518 - 1519. [Full Text] [PDF]
|
|
|
|
|
|
A. Muscari, A. Berzigotti, G. Bianchi, C. Giannoni, A. Ligabue, D. Magalotti, D. Sbano, A. Zacchini, and M. Zoli Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis Eur J Heart Fail, August 1, 2006; 8(5): 468 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I.W. Galasko, A. Lahiri, S. C. Barnes, P. Collinson, and R. Senior What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur. Heart J., November 1, 2005; 26(21): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Norozi, R. Buchhorn, C. Kaiser, G. Hess, R. W. Grunewald, L. Binder, and A. Wessel Plasma N-Terminal Pro-Brain Natriuretic Peptide as a Marker of Right Ventricular Dysfunction in Patients With Tetralogy of Fallot After Surgical Repair Chest, October 1, 2005; 128(4): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S G Williams, L L Ng, R J O'Brien, D Barker, Y-F Li, and L-B Tan Safe use of brain natriuretic protein to rule out the diagnosis of heart failure depends on the selection of cut off value Heart, August 1, 2005; 91(8): 1090 - 1091. [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, D. Mortl, O. Gore, B. Meyer, and R. Pacher Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: A direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide Eur J Heart Fail, June 1, 2005; 7(4): 552 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF]
|
|